{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"74.5","upperLimit":"88.3","value":"82.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"129"}],"units":"Participants"}],"description":"Clinical benefit was evaluated according to RECIST 1.0 by independent review assessment. Patients whose best RECIST 1.0 assessment was stable disease (SD), partial response (PR), or complete response (CR) were considered to have derived a clinical benefit from treatment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients in the four initial cohorts are combined in the efficacy presentations. Patients start once daily oral treatment of BIBW 2992 (Afatinib) at 50 mg before protocol amendment 2 (17 Dec 2008), until progression or undue adverse events (AEs) development. Patients can be dose-reduced up to two times if needed after temporary interruption of treatment due to drug- related AEs. After protocol amendment 2, the starting dose of BIBW 2992 was reduced to 40 mg, with 2 possible dose reductions if needed after temporary dose interruption due to drug-related AEs.","id":"OG000","title":"Afatinib"}],"paramType":"NUMBER","populationDescription":"Treated set","reportingStatus":"POSTED","timeFrame":"Response assessment is done at end of Week 4 (after Course 1), Week 8 (after Course 2), Week 12 (after Course 3) and at 8-week intervals thereafter, up to 93 months.","title":"Clinical Benefit as Determined by RECIST 1.0","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}